NageatteIbrahimMD

PubMed

• Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases.
  Jennifer E Yeh, Marilyn T Wan, Allireza Alloo, Nageatte Ibrahim, Ivan Buzurovic, Jeffrey M Cohen, Patrick A Ott, Alvaro C Laga, Phillip M Devlin, Jennifer Y Lin> ;JAAD Case Reports. 2023 Jan 1
• 1 citations
  Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma.
  Jennifer E Yeh, Marilyn T Wan, Allireza Alloo, Nageatte Ibrahim, Patrick A Ott, Elizabeth I Buchbinder, Jennifer Y Lin> ;JAAD Case Reports. 2022 Sep 1
• Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply.
  Jason J Luke, Nageatte Ibrahim, Alexander Mm Eggermont> ;Lancet. 2022 Aug 20
• 163 citations
  Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
  Jason J Luke, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Muhammad A Khattak, Dirk Schadendo...> ;Lancet. 2022 Apr 30
• 17 citations
  Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.
  Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khusha...> ;Cancer Discovery. 2021 Nov 11
• 4 citations
  Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
  Georgina V. Long, A. Arance, Laurent Mortier, Paul Lorigan, Christian U. Blank, Peter Mohr, Jacob Schachter, J.-J. Grob, Michal Lotem, Mark R. Middleton, Bart Neyns, N...> ;Annals of Oncology. 2021 Oct 25
• 17 citations
  Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete rese...
  Alexander M.M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandalà, Georgina V. Long, Catherine Barrow, Anna Maria Di Giacomo, Rosali...> ;European Journal of Cancer. 2021 Oct 18
• 183 citations
  Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomi...
  Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, M...> ;The Lancet. Oncology. 2021 May 1
• 32 citations
  Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomise...
  Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Mesh...> ;The Lancet. Oncology. 2021 May 1
• Reply to E. Hindié.
  Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, ...> ;Journal of Clinical Oncology. 2021 Mar 10
• 48 citations
  Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
  , , , , , , , , , , , , , , , , , , , , , > ;European Journal of Cancer. 2021 Feb 1
• 5 citations
  Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.
  Kristen L. Mueller, Marc R. Theoret, Steven Lemery, Laleh Amiri-Kordestani, Charlotte E. Ariyan, Michael B. Atkins, Donald A. Berry, Christian U. Blank, Angela DeMiche...> ;Clinical Cancer Research. 2021 Jan 15
• 19 citations
  Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
  Georgina V. Long, Caroline Robert, Marcus O. Butler, Félix Couture, Matteo S. Carlino, Steven J. O'Day, Victoria Atkinson, Jonathan Cebon, Michael P. Brown, Stéphane D...> ;Clinical Cancer Research. 2021 Jul 1
• Reply to E. Hindié.
  Andrea Maurichi, Rosalba Miceli, Hanna Eriksson, Julia Newton-Bishop, Jérémie Nsengimana, May Chan, Andrew J Hayes, Kara Heelan, David Adams, Roberto Patuzzo, Francesc...> ;Journal of Clinical Oncology. 2020 Sep 20
• 160 citations
  Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-05...
  Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, M...> ;Journal of Clinical Oncology. 2020 Sep 18
• 36 citations
  Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
  Igor Puzanov, Antoni Ribas, Caroline Robert, Jacob Schachter, Marta Nyakas, Adil Daud, Ana Arance, Matteo S. Carlino, Steven J. O'Day, Georgina V. Long, Kim Margolin, ...> ;JAMA Oncology. 2020 Aug 1
• 23 citations
  Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B.
  Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan Cebon, Michael B. Jameson, Fitzharris Bm, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michae...> ;Clinical Cancer Research. 2020 Oct 1
• 101 citations
  Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
  , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2020 May 1
• 256 citations
  Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A...
  Alexander M.M. Eggermont, Michal Kicinski, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Adnan Khattak, Matteo...> ;JAMA Oncology. 2020 Jan 2
• 50 citations
  KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
  Jason J. Luke, Paolo A. Ascierto, Matteo S. Carlino, Jeffrey E. Gershenwald, Jean-Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Carolin...> ;Future Oncology. 2020 Jan 1
• 653 citations
  Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
  Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James L...> ;The Lancet. Oncology. 2019 Jul 22
• 5 citations
  Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
  Antoni Ribas, Donald P. Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H. Miller, Matteo S. Carlino, Rosalie Fisher, Georgina V. Long, F. Stephen Hodi, Jennifer T...> ;Nature Medicine. 2019 Jul 2
• 54 citations
  Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
  Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Ma...> ;European Journal of Cancer. 2019 Jul 1
• 219 citations
  Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
  Antoni Ribas, Donald P. Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H. Miller, Matteo S. Carlino, Rosalie Fisher, Georgina V. Long, F. Stephen Hodi, Jennifer T...> ;Nature Medicine. 2019 Jun 6
• 208 citations
  Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
  Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, ...> ;Nature Medicine. 2019 Jun 1
• Join now to see all

Journal Articles

• Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma  
  Igor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology